The United States Treasury Department has proposed a major revision of rules governing American investments in sensitive foreign technologies, expanding scrutiny of transactions involving advanced artificial intelligence, semiconductors, biotechnology and other sectors with possible military applications. The proposed regulations, announced on October 22, 2026, implement provisions of the Comprehensive Outbound Investment National Security Act, known as the COINS Act, enacted by Congress in 2025. The measures are intended to prevent American capital and associated technical knowledge from contributing to capabilities that Washington considers threats to national security.
The proposal builds on the Outbound Investment Security Program, which already restricts certain American investments involving China and specified advanced technologies. The updated framework adds further categories, including high-performance computing, hypersonic systems and biotechnology, while retaining distinctions between transactions that would be prohibited and those requiring notification to the government.
Treasury has opened a public consultation period ending December 7, 2026. The proposed provisions have not all entered into force, making it essential to distinguish the rules currently operating from the additional restrictions being considered.
Why is Washington expanding controls on American investments abroad?
The administration argues that some overseas investments can provide more than financial capital. They may also facilitate technical knowledge, management expertise and commercial relationships that help foreign businesses develop sensitive capabilities.
The existing framework was introduced to address concerns involving technologies with potential military, surveillance and intelligence uses. Congress subsequently codified and expanded that approach through the COINS Act.
Treasury Secretary Scott Bessent presented the proposal as an attempt to protect American national-security interests while providing greater clarity to investors. The government’s stated objective is not to prohibit every investment involving China but to restrict transactions associated with defined sensitive technologies.
The policy consequently differs from ordinary tariffs on imported goods. It concerns the flow of American investment and associated participation in foreign technology businesses.
Which technologies are covered by the proposed rules?
The Treasury proposal covers semiconductor technologies and microelectronics, artificial intelligence systems, quantum information technologies, high-performance computing and supercomputing, and hypersonic systems.
It also proposes adding biotechnology, a significant development because of the growing international commercial connections between pharmaceutical and life-sciences companies.
Different technical categories may be subject to different restrictions. Certain advanced applications could be prohibited, while others may trigger a notification requirement rather than an outright ban.
The exact boundary will depend on definitions, performance thresholds and the final regulations. A broad sector name such as artificial intelligence does not mean every software company or transaction is automatically covered.
Why has biotechnology become a national-security concern?
Biotechnology can support medical advances, agricultural applications and industrial innovation. Some technologies also have potential uses involving biological threats, surveillance or military capabilities.
The U.S. government argues that those dual-use characteristics justify examining certain investments more closely. The proposal includes technical categories associated with sensitive biological research and development.
However, the biotechnology sector encompasses products and activities with very different risk profiles. A cancer treatment developed through ordinary commercial research is not necessarily equivalent to a technology designed for a prohibited military use.
The challenge for regulators is creating definitions that address national-security concerns without unnecessarily restricting beneficial scientific activity. That issue is likely to feature prominently during consultation.
Will American pharmaceutical companies be prohibited from licensing Chinese drugs?
The proposal has attracted attention because American and European pharmaceutical companies increasingly use licensing arrangements to obtain rights to therapies developed by Chinese biotechnology businesses.
Such agreements differ from equity investments. A company may purchase commercial rights to a medicine or technology without acquiring ownership in the developer.
Treasury’s existing framework and the proposed rules contain exceptions for certain transactions, while the treatment of specific licensing structures depends on their terms. The announcement does not establish a universal ban on pharmaceutical licensing deals.
Business groups have expressed concern about regulatory uncertainty. Companies will need to examine whether an agreement involves covered ownership interests, restricted technologies or other activities falling within the final definitions.
What changes for venture capital, joint ventures and technology partnerships?
Direct investment in sensitive businesses may be treated differently from the purchase of ordinary publicly traded shares or a conventional commercial supply agreement.
The proposed rules address covered transactions, the conduct of American persons and their controlled foreign entities, and the circumstances in which prior knowledge or reasonable diligence becomes relevant.
This creates potential compliance obligations for investors evaluating foreign technology companies. Due diligence may need to examine the target’s technical activities rather than rely solely on its general industry classification.
Joint ventures can raise additional questions because they may involve operational participation as well as funding. Their treatment will depend on the final rules and the nature of the technology concerned.
Does the proposal apply only to China?
The existing programme has focused heavily on China, including Hong Kong and Macau, but the expanded framework addresses additional designated countries of concern and their involvement in sensitive technologies.
The precise country definitions and transaction rules matter because a business incorporated outside a listed country may still have ownership or operational connections that require examination.
Investors should therefore avoid assuming that a transaction is automatically exempt simply because the immediate contracting entity is located in another jurisdiction.
At the same time, not every investment connected with an affected country is necessarily prohibited. The regulation operates through defined categories and exceptions.
When could the new restrictions take effect?
Treasury has invited comments through December 7, 2026. The department will review submissions before issuing final implementing regulations with an effective date.
The consultation period creates an opportunity for technology companies, investors, pharmaceutical businesses and other stakeholders to explain potential compliance difficulties or unintended consequences.
Until final rules are adopted, the newly proposed provisions should not be described as already enforceable restrictions. The existing outbound investment programme continues to operate separately.
The next important milestone is the final regulation and the technical definitions governing specific transactions.
What are the key takeaways from the US outbound investment proposal?
The Treasury Department proposed expanded restrictions on American investment in sensitive foreign technologies on October 22. The framework covers artificial intelligence, semiconductors, quantum technology, advanced computing, hypersonic systems and biotechnology.
Some transactions could be prohibited while others would require notification. The proposal does not establish an across-the-board ban on dealings with Chinese technology companies, and final rules will follow the public consultation ending December 7.
What will determine the proposal’s impact on global technology investment?
The decisive questions concern the final technical definitions, the treatment of existing business arrangements and the scope of applicable exceptions. Those details will determine which investments must be restructured, reported or abandoned.
The broader policy direction is clear: Washington is seeking greater control over the contribution of American capital to selected foreign technologies. The actual commercial impact will become measurable once the regulations are finalised and companies begin applying them.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
